Aptose Biosciences effects 1-for-15 reverse stock split, trading starts June 6

Aptose Biosciences Inc.

Shareholders approved ratio range 1-for-10 to 1-for-20 at May 23, 2023 meeting; board set final ratio at 1-for-15.
Articles of amendment filed under CBCA on May 24, 2023; split-adjusted trading begins on Nasdaq and TSX on June 6, 2023.
Post-split shares outstanding approximately 6.3 million; no fractional shares issued, rounded down.
Common shares continue trading under symbols APTO (Nasdaq) and APS (TSX); new CUSIP 03835T309 and ISIN CA03835T3091.
Proportionate adjustments made to exercise prices and shares underlying outstanding equity awards and plans.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aptose Biosciences Inc.: Filed articles of amendment to implement a 1-for-15 reverse stock split (effective 2023-06-06).

Change: charter amendment
Effective: 2023-06-06

Exact text from the filing

The following day, the Company filed articles of amendment under the Canadian Business Corporations Act to implement the Reverse Stock Split.

View on SEC.gov

Browse all governance changes →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-003757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.